A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Conditions
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
VA Greater LA Healthcare System, Los Angeles, California, United States
Contact: Principal Investigator (Matthew Rettig)Rio Grande Urology, El Paso, Texas, United States
Contact: Principal Investigator (Jameson T Mendel)Utah Intermountain Medical Center, Murray, Utah, United States
Contact: Principal Investigator (Dustin Boothe)Novartis Investigative Site, Malvern, Victoria, Australia
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Murdoch, Western Australia, Australia
Novartis Investigative Site, Bordeaux, France
Novartis Investigative Site, Clermont-Ferrand, France
Novartis Investigative Site, Nantes, France
Novartis Investigative Site, Villejuif, France
Novartis Investigative Site, Dresden, Saxony, Germany
Novartis Investigative Site, Essen, Germany
Novartis Investigative Site, München, Germany
Novartis Investigative Site, Cona, FE, Italy
Novartis Investigative Site, Milan, MI, Italy
Novartis Investigative Site, Naples, Italy
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Granada, Andalusia, Spain
Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site, Barcelona, Spain
Novartis Investigative Site, Madrid, Spain
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals